This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
250mg | $1550 | Check With Us |
500mg | $2350 | Check With Us |
1g | $3525 | Check With Us |
Cat #: V3709 CAS #: 1431699-67-0 Purity ≥ 98%
Description: (S)-Tedizolid is the S-enantiomer of Tedizolid (TR-700; DA-7157; Sivextro), which is an antibiotic that gained FDA approval in 2014 for the treatment of acute bacterial skin and skin structure infections. Tedizolid acts as an inhibitor of bacterial protein synthesis by binding to the 50S ribosomal subunit of the G+ bacteria.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 370.34 |
---|---|
Molecular Formula | C₁₇H₁₅FN₆O₃ |
CAS No. | 1431699-67-0 |
Storage | -20℃ for 3 years in powder formr |
-80℃ for 2 years in solvent | |
Solubility In Vitro | DMSO: ≥ 10 mMr |
Water: ≥ 1 mg/mLr | |
Ethanol: ≥ 1 mg/mL | |
Synonyms | (S)-DA-7157; (S)-DA7157; DA 7157; (S)-TR-700; (S)-TR 700; TR700; (S)-Tedizolid; (S)-Torezolid. |
Protocol | In Vitro | In vitro activity: Tedizolid (formerly known as torezolid, TR-700, or DA-7157, trade name Sivextro), is an oxazolidinone-class antibiotic against Gram-positive bacteria. The mechanism of action is to inhibit protein synthesis by binding to the 50S ribosomal subunit of the G+ bacteria. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (formerly Dong-A Pharmaceuticals in Korea), and is approved in 2014 by the US-FDA for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)). Kinase Assay: Tedizolid (0.25 μg/mL) inhibits all 28 clinical isolates of PRSP, and is 4-fold more potent than linezolid against PRSP Cell Assay: Tedizolid (0.25 μg/mL) inhibits all 28 clinical isolates of PRSP, and is 4-fold more potent than linezolid against PRSP |
---|---|---|
In Vivo | Male ICR mice (weight, 18 to 20 g) are inoculated intraperitoneally with 1 of 4 PRSP isolates (DR9, DR10, DR11, or DR14) suspended in 10% mucin, to induce a systemic S. pneumoniae infection. The suspension contained sufficient bacteria to kill 100% of untreated control mice. At 1 h postinfection, mice receives a single dose of either tedizolid phosphate or linezolid, and survival is assessed daily for 7 days postinfection. Treatments are delivered both orally and intravenously at each of four doses (40 mg/kg of body weight, 13.33 mg/kg, 4.44 mg/kg, and 1.48 mg/kg), with 8 mice per group defined by dose, delivery method, and infecting strain. The 50% effective dose (ED50), i.e., the dose allowing survival of 50% of the infected mice, is calculated for each delivery route using probit analysis. | |
Animal model | Male ICR mice (weight, 18 to 20 g) are inoculated intraperitoneally with 1 of 4 PRSP isolates (DR9, DR10, DR11, or DR14) suspended in 10% mucin, to induce a systemic S. pneumoniae infection. | |
Dosages | 40 mg/kg of body weight, 13.33 mg/kg, 4.44 mg/kg, and 1.48 mg/kg | |
Administration | i.p. |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 2.7002 mL | 13.5011 mL | 27.0022 mL | 54.0044 mL |
5mM | 0.5400 mL | 2.7002 mL | 5.4004 mL | 10.8009 mL |
10mM | 0.2700 mL | 1.3501 mL | 2.7002 mL | 5.4004 mL |
20mM | 0.1350 mL | 0.6751 mL | 1.3501 mL | 2.7002 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.